277.22
price up icon2.43%   6.58
after-market After Hours: 277.22
loading
Penumbra Inc stock is traded at $277.22, with a volume of 728.38K. It is up +2.43% in the last 24 hours and down -1.13% over the past month. Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
See More
Previous Close:
$270.64
Open:
$274
24h Volume:
728.38K
Relative Volume:
1.59
Market Cap:
$10.53B
Revenue:
$1.16B
Net Income/Loss:
$34.55M
P/E Ratio:
322.35
EPS:
0.86
Net Cash Flow:
$134.18M
1W Performance:
+1.82%
1M Performance:
-1.13%
6M Performance:
+34.82%
1Y Performance:
+36.56%
1-Day Range:
Value
$270.02
$277.22
1-Week Range:
Value
$268.15
$280.77
52-Week Range:
Value
$148.00
$310.00

Penumbra Inc Stock (PEN) Company Profile

Name
Name
Penumbra Inc
Name
Phone
(510) 995-2486
Name
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Name
Employee
4,500
Name
Twitter
@penumbrainc
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
PEN's Discussions on Twitter

Compare PEN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
PEN
Penumbra Inc
277.22 10.53B 1.16B 34.55M 134.18M 0.86
Medical Devices icon
ABT
Abbott Laboratories
131.73 218.91B 41.95B 13.40B 6.35B 7.65
Medical Devices icon
BSX
Boston Scientific Corp
95.05 139.37B 16.75B 1.85B 2.37B 1.25
Medical Devices icon
SYK
Stryker Corp
348.12 134.90B 22.60B 2.99B 3.49B 7.76
Medical Devices icon
MDT
Medtronic Plc
83.37 106.90B 33.20B 4.26B 5.47B 3.29
Medical Devices icon
EW
Edwards Lifesciences Corp
70.60 41.45B 5.72B 4.17B 259.90M 6.97

Penumbra Inc Stock (PEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-14-25 Initiated BofA Securities Buy
Jan-21-25 Initiated UBS Buy
Dec-17-24 Initiated Oppenheimer Outperform
Dec-11-24 Upgrade Wells Fargo Equal Weight → Overweight
Sep-18-24 Initiated Stifel Buy
Sep-03-24 Initiated Leerink Partners Outperform
Jul-31-24 Downgrade Citigroup Buy → Neutral
Jul-31-24 Downgrade Wells Fargo Overweight → Equal Weight
Feb-23-24 Downgrade JP Morgan Overweight → Neutral
Sep-06-23 Initiated Morgan Stanley Equal-Weight
Jul-19-23 Initiated Robert W. Baird Outperform
Mar-29-23 Downgrade Needham Buy → Hold
Jan-30-23 Initiated Piper Sandler Overweight
Nov-04-22 Upgrade Citigroup Neutral → Buy
Oct-12-22 Initiated Jefferies Buy
Oct-05-22 Downgrade Citigroup Buy → Neutral
Sep-09-22 Upgrade Needham Hold → Buy
Jul-18-22 Initiated RBC Capital Mkts Outperform
Apr-19-22 Initiated Deutsche Bank Buy
Mar-08-22 Initiated Needham Hold
Sep-16-21 Initiated Truist Buy
Jun-04-21 Upgrade BTIG Research Neutral → Buy
Dec-16-20 Downgrade BTIG Research Buy → Neutral
Oct-07-20 Resumed Canaccord Genuity Buy
Sep-29-20 Initiated BTIG Research Buy
Sep-08-20 Downgrade BofA Securities Buy → Neutral
Mar-05-20 Initiated Citigroup Buy
Jun-13-19 Reiterated BofA/Merrill Buy
May-30-19 Upgrade JP Morgan Neutral → Overweight
May-21-19 Initiated William Blair Outperform
Oct-29-18 Resumed BofA/Merrill Buy
Oct-08-18 Initiated RBC Capital Mkts Outperform
Feb-21-18 Initiated William Blair Outperform
Jan-02-18 Downgrade JP Morgan Overweight → Neutral
Nov-30-15 Reiterated Canaccord Genuity Buy
Oct-13-15 Initiated Wells Fargo Outperform
View All

Penumbra Inc Stock (PEN) Latest News

pulisher
Apr 22, 2025

What To Expect From Penumbra’s (PEN) Q1 Earnings - Yahoo Finance

Apr 22, 2025
pulisher
Apr 21, 2025

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GlobeNewswire

Apr 21, 2025
pulisher
Apr 21, 2025

Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again - Yahoo Finance

Apr 21, 2025
pulisher
Apr 21, 2025

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits (PR Newswire) - Aktiellt

Apr 21, 2025
pulisher
Apr 18, 2025

Penumbra CEO Adam Elsesser sells $4.54 million in stock By Investing.com - Investing.com South Africa

Apr 18, 2025
pulisher
Apr 18, 2025

Penumbra CEO Adam Elsesser sells $4.54 million in stock - Investing.com

Apr 18, 2025
pulisher
Apr 18, 2025

Penumbra director O’Rourke sells shares worth $13,560 By Investing.com - Investing.com South Africa

Apr 18, 2025
pulisher
Apr 17, 2025

Penumbra director O’Rourke sells shares worth $13,560 - Investing.com

Apr 17, 2025
pulisher
Apr 16, 2025

Investors more bullish on Penumbra (NYSE:PEN) this week as stock lifts 6.4%, despite earnings trending downwards over past five years - simplywall.st

Apr 16, 2025
pulisher
Apr 16, 2025

Penumbra (PEN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

RBC Lifts Price Target on Penumbra to $315 From $313, Keeps Outperform Rating - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

BTIG Adjusts Penumbra (PEN) Price Target as MedTech Q1 Results L - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Micro Guide Catheters Market to Witness Remarkable Growth with - openPR.com

Apr 14, 2025
pulisher
Apr 12, 2025

Truist Adjusts Price Target for Penumbra (PEN) Amid Market Volat - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Truist Cuts Price Target on Penumbra to $315 From $325, Keeps Buy Rating - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Penumbra price target lowered to $315 from $325 at Truist - TipRanks

Apr 11, 2025
pulisher
Apr 10, 2025

Is Penumbra Gaining or Losing Market Support? - Benzinga

Apr 10, 2025
pulisher
Apr 09, 2025

3 Reasons PEN is Risky and 1 Stock to Buy Instead - The Globe and Mail

Apr 09, 2025
pulisher
Apr 09, 2025

PEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Penumbra, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm - marketscreener.com

Apr 09, 2025
pulisher
Apr 08, 2025

Reasons to Retain Penumbra Stock in Your Portfolio for Now - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Penumbra, Inc. (NYSE: PEN) - PR Newswire

Apr 08, 2025
pulisher
Apr 06, 2025

(PEN) Trading Report - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 05, 2025

Penumbra Inc director Wilder Thomas sells $96,094 in stock By Investing.com - Investing.com India

Apr 05, 2025
pulisher
Apr 04, 2025

Penumbra CEO Adam Elsesser sells $4.5 million in stock By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Penumbra CEO Adam Elsesser sells $4.5 million in stock - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Penumbra Inc director Wilder Thomas sells $96,094 in stock - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 - BioSpace

Apr 04, 2025
pulisher
Apr 03, 2025

Penumbra Q1 2025 Earnings Date Confirmed: Key Details for Investors - Stock Titan

Apr 03, 2025
pulisher
Apr 03, 2025

Penumbra EVP Johanna Roberts sells $161,466 in stock By Investing.com - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Penumbra director Harpreet Grewal sells $53,434 in stock By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 02, 2025

Penumbra director Wilder Thomas sells $95,248 in common stock - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Penumbra director Harpreet Grewal sells $53,434 in stock - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vac - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

Breakthrough Clinical Data: Penumbra's CAVT Slashes Hospital Stays by 46%, Achieves 99% Success Rate - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

Meiji Yasuda Asset Management Co Ltd. Buys New Position in Penumbra, Inc. (NYSE:PEN) - MarketBeat

Apr 01, 2025
pulisher
Mar 29, 2025

ROSEN, A LEADING LAW FIRM, Encourages Penumbra, Inc. Investors to Secure Counsel Before Important March 16 DeadlinePEN - PR Newswire

Mar 29, 2025
pulisher
Mar 28, 2025

Penumbra Insider Sold Shares Worth $3,405,253, According to a Recent SEC Filing - MarketScreener

Mar 28, 2025
pulisher
Mar 27, 2025

Penumbra director Arani sells $3.41 million in stock - Investing.com India

Mar 27, 2025
pulisher
Mar 26, 2025

Thrombectomy Devices Market Surge: Key Players & Future Outlook - openPR.com

Mar 26, 2025
pulisher
Mar 25, 2025

New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues - MSN

Mar 25, 2025
pulisher
Mar 24, 2025

Imperative Care Expands Precision Thrombectomy Portfolio - Diagnostic and Interventional Cardiology

Mar 24, 2025
pulisher
Mar 22, 2025

Penumbra CEO Adam Elsesser sells $4.59 million in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 21, 2025

Penumbra CEO Adam Elsesser sells $4.59 million in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Do Its Financials Have Any Role To Play In Driving Penumbra, Inc.'s (NYSE:PEN) Stock Up Recently? - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Has Penumbra, Inc.'s (NYSE:PEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - simplywall.st

Mar 21, 2025

Penumbra Inc Stock (PEN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices ZBH
$97.44
price up icon 1.32%
medical_devices PHG
$24.14
price up icon 3.65%
medical_devices STE
$222.77
price up icon 1.82%
$66.33
price up icon 0.33%
$61.65
price up icon 1.93%
medical_devices EW
$70.60
price up icon 2.02%
Cap:     |  Volume (24h):